Gilead Sciences, Inc. GILD NDXSPX
Company Overview
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Why Investors Should Care
Generates a return on equity of 43.4%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 21.2%.
Revenue has grown at a 11.4% CAGR over the past five years.
Trades at a P/E of 17.7, below the sector median of 25.4.
Maintains a net profit margin of 31.0%.
Offers a dividend yield of 2.61%.
Recent Developments
- Dec 2025 Revenue of $29.44B (+2.4% YoY); net profit $8.51B.
- Trailing 12 Months Year-on-year growth — revenue +4.4%, earnings +54.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 11.4%, profit CAGR 9.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 11.38% |
| 1 Year: | 4.40% |
Compounded Profit Growth
| 5 Years: | 9.79% |
| 1 Year: | 54.80% |
Stock Price Performance
| 1 Year: | +19.04% |
| 6 Months: | +8.70% |
| 3 Months: | -5.85% |
| 1 Month: | +3.99% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)51.18 · Neutral
P/E of 17.69 is below the sector median of 25.41 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 43.4%.
- Healthy ROCE of 21.2%.
- Excellent profit margin of 31.0%.
- Compounding revenue at 11.4% over 5 years.
- Attractive dividend yield of 2.61%.
- Generates positive free cash flow.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GILD Gilead Sciences, Inc. NDXSPX | 130.04 | 17.69 | $161.45B | 2.61% | 21.23% | 43.36% | 11.38% | 9.79% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 5.09B | 5.65B | 5.60B | - | 5.28B | 5.68B | 5.60B | - | 5.55B | 5.14B | 6.58B | - | 6.42B | 6.22B | 7.42B | 6.59B | 6.26B | 7.04B | 6.35B | 6.60B | 7.05B | 6.69B | 6.95B | 7.54B | 6.67B | 7.08B | 7.77B | 6.96B |
| Gross Profit | 6.52B | 7.13B | 7.15B | 7.35B | 6.49B | 6.79B | 6.28B | 6.14B | 5.42B | 5.92B | 5.37B | 4.58B | 4.00B | 4.34B | 4.37B | 4.11B | 4.24B | 4.61B | 4.48B | 4.11B | 4.50B | 4.00B | 5.35B | 5.93B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | 5.37B | 5.62B | 5.58B | - | 4.65B | 4.54B | 4.40B | - | 3.77B | 4.25B | 3.81B | - | 2.15B | 2.28B | 2.62B | - | 2.24B | 2.43B | -1.47B | - | 2.40B | -2.98B | 2.00B | - | 2.89B | 2.25B | 3.84B | 197.00M | 2.03B | 2.84B | 1.71B | 1.67B | 2.62B | -4.32B | 2.64B | 888.00M | 2.24B | 2.47B | 3.33B | 2.59B |
| Net Income | 4.33B | 4.49B | 4.60B | 4.68B | 3.57B | 3.50B | 3.33B | 3.11B | 2.70B | 3.07B | 2.72B | -3.87B | 1.54B | 1.82B | 2.10B | 3.00M | 1.98B | 1.88B | -1.17B | 2.70B | 1.55B | -3.34B | 360.00M | 1.55B | 1.73B | 1.52B | 2.59B | 19.00M | 1.14B | 1.79B | 1.01B | 1.04B | 2.18B | -4.17B | 1.61B | 1.25B | 1.31B | 1.96B | 3.05B | 2.02B |
| Diluted EPS | 2.76 | 2.92 | 3.06 | 3.18 | 2.53 | 2.58 | 2.49 | 2.34 | 2.05 | 2.33 | 2.06 | -2.96 | 1.17 | 1.39 | 1.60 | 0.00 | 1.54 | 1.47 | -0.92 | 2.12 | 1.22 | -2.66 | 0.29 | 1.23 | 1.37 | 1.21 | 2.05 | 0.02 | 0.91 | 1.42 | 0.80 | 0.83 | 1.73 | -3.34 | 1.29 | 1.00 | 1.04 | 1.56 | 2.43 | 1.61 |
| R&D Expense | 696.00M | 818.00M | 743.00M | - | 1.26B | 1.48B | 1.14B | - | 931.00M | 864.00M | 789.00M | - | 937.00M | 1.19B | 939.00M | - | 1.06B | 1.16B | 4.99B | - | 1.10B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.23B | 5.34B | 7.01B | 7.95B | 8.39B | 9.70B | 11.20B | 24.89B | 32.64B | 30.39B | 26.11B | 22.13B | 22.45B | 24.69B | 27.30B | 27.28B | 27.12B | 28.75B | 29.44B |
| Operating Income | 2.16B | 2.68B | 3.53B | 3.96B | 3.79B | 4.01B | 4.52B | 15.27B | 22.19B | 17.63B | 14.12B | 8.20B | 4.29B | 4.07B | 9.92B | 7.33B | 7.61B | 1.66B | 10.02B |
| Net Income | 1.58B | 1.98B | 2.64B | 2.90B | 2.80B | 2.59B | 3.08B | 12.10B | 18.11B | 13.50B | 4.63B | 5.46B | 5.39B | 123.00M | 6.22B | 4.59B | 5.67B | 480.00M | 8.51B |
| Diluted EPS | 1.64 | 2.06 | 2.82 | 1.66 | 1.77 | 1.64 | 1.81 | 7.35 | 11.91 | 9.94 | 3.51 | 4.17 | 4.22 | 0.10 | 4.93 | 3.64 | 4.50 | 0.38 | 6.78 |
| R&D Expense | - | - | - | - | 1.23B | 1.76B | 2.12B | 2.85B | 3.01B | 5.10B | 3.73B | 5.02B | 9.11B | - | - | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 6.94B | 9.70B | 11.59B | 17.30B | 21.24B | 22.58B | 34.66B | 51.72B | 56.98B | 70.28B | 63.67B | 61.63B | 68.41B | 67.95B | 63.17B | 62.12B | 58.99B | 59.02B |
| Total Equity | 2.05B | 3.75B | 4.27B | 6.37B | 5.86B | 6.74B | 9.30B | 11.37B | 15.43B | 18.53B | 18.89B | 20.44B | 21.39B | 22.52B | 18.20B | 21.07B | 21.24B | 22.83B | 19.33B | 22.70B |
| Cash & Equivalents | 816.01M | 968.09M | 1.46B | 1.27B | 907.88M | 9.88B | 1.80B | 2.11B | 10.03B | 12.85B | 8.23B | 7.59B | 17.94B | 11.63B | 6.00B | 5.34B | 5.41B | - | - | - |
| Long Term Debt | - | - | - | - | - | 7.61B | 7.05B | 3.94B | 11.92B | 21.07B | 26.35B | 30.80B | 24.57B | 22.09B | 28.64B | 25.18B | 22.96B | 23.19B | 24.90B | 22.13B |
| Current Liabilities | - | - | 1.22B | 1.87B | 2.46B | 2.51B | 4.24B | 6.41B | 5.76B | 9.89B | 9.22B | 11.63B | 10.61B | 9.76B | 11.40B | 11.61B | 11.24B | 11.28B | 12.00B | 11.81B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 1.67B | 2.14B | 3.08B | 2.83B | 3.64B | 3.19B | 3.10B | 12.82B | 21.25B | 17.05B | 11.90B | 8.40B | 9.14B | 8.17B | 11.38B | 9.07B | 8.01B | 10.83B | 10.02B |
| Investing Cash Flow | -1.30B | -178.82M | -2.22B | -1.94B | 3.59B | -11.85B | -254.00M | -1.82B | -12.47B | -11.98B | -16.07B | 14.36B | -7.82B | -14.62B | -3.13B | -2.47B | -2.27B | -3.45B | -4.79B |
| Financing Cash Flow | -170.98M | -1.47B | -1.05B | -1.34B | 1.76B | 563.00M | -2.54B | -3.02B | -5.88B | -9.72B | 3.39B | -12.32B | -7.63B | 770.00M | -8.88B | -6.47B | -5.12B | -3.43B | -7.75B |
| Capital Expenditure | - | - | - | - | - | - | -134.00M | - | - | - | - | -924.00M | -825.00M | -650.00M | -579.00M | -728.00M | -585.00M | -523.00M | -563.00M |
| Free Cash Flow | - | - | - | - | - | - | 2.97B | - | - | - | - | 7.48B | 8.32B | 7.52B | 10.80B | 8.34B | 7.42B | 10.30B | 9.46B |
| Share Buybacks | 487.54M | 1.97B | 998.50M | 4.02B | 2.38B | 667.00M | 582.00M | 5.35B | 10.00B | 11.00B | 954.00M | 2.90B | 1.75B | 1.58B | 546.00M | 1.40B | 1.00B | 1.15B | 1.92B |
| Dividends Paid | - | - | - | - | - | - | 0 | 0 | 1.87B | 2.46B | 2.73B | 2.97B | 3.22B | 3.45B | 3.60B | 3.71B | 3.81B | 3.92B | 4.00B |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | 51.2% | 50.2% | 50.3% | 49.8% | 45.2% | 41.3% | 40.4% | 61.3% | 68.0% | 58.0% | 54.1% | 37.1% | 19.1% | 16.5% | 36.3% | 26.9% | 28.0% | 5.8% | 34.0% |
| Net Margin % | 37.5% | 37.1% | 37.6% | 36.5% | 33.4% | 26.7% | 27.5% | 48.6% | 55.5% | 44.4% | 17.7% | 24.7% | 24.0% | 0.5% | 22.8% | 16.8% | 20.9% | 1.7% | 28.9% |
| ROE % | 42.2% | 46.3% | 41.4% | 49.5% | 41.6% | 27.9% | 27.0% | 78.4% | 97.7% | 71.5% | 22.6% | 25.5% | 23.9% | 0.7% | 29.5% | 21.6% | 24.8% | 2.5% | 37.5% |
| ROCE % | - | 46.9% | 45.1% | 43.4% | 25.6% | 23.6% | 28.0% | 52.8% | 53.1% | 36.9% | 24.1% | 15.5% | 8.3% | 7.1% | 17.6% | 14.1% | 15.0% | 3.5% | 21.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 9.59% | 119.01M | $15.35B |
| 2 | Vanguard Capital Management LLC | 6.50% | 80.65M | $10.40B |
| 3 | FMR, LLC | 5.79% | 71.91M | $9.27B |
| 4 | State Street Corporation | 4.82% | 59.86M | $7.72B |
| 5 | Capital World Investors | 3.33% | 41.28M | $5.32B |
| 6 | Vanguard Portfolio Management LLC | 2.83% | 35.13M | $4.53B |
| 7 | JPMORGAN CHASE & CO | 2.74% | 33.99M | $4.38B |
| 8 | Geode Capital Management, LLC | 2.39% | 29.73M | $3.83B |
| 9 | Capital Research Global Investors | 2.18% | 27.13M | $3.50B |
| 10 | Price (T.Rowe) Associates Inc | 2.11% | 26.25M | $3.38B |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GILD
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxQclR2UzJHMm1iZG44T2dzUFpGQmh5aDVsYmI2ejZkVFk1amV2Y29QbmFCTEdzQXJvMzYwYzJoY2dvRV96RTJxQkt2dUJCV2pobDN0YnpHTmx5TlA3TnA2ZHdRM29KRkZJRjFxNEk3X3piWGFzU0FhV1ZabkFYcXZPcVNpMlpNYTFaelY5a3…
Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1 - StockStory
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxOUVdGT3hnQnNuR0llWHpSVk5aYldTU3NFTWJ5N25GNzJwNW9pZ0dNV2RFWHI1LUNnTWg0UmlxOG42aXI0OUpkWGIydlNLTkJReWFXS09scERaZ0hHakctTUhSVVVyalVxLXRad1EzUVEwSmQwcG1HcUlFVUV4T1VGdTlvaTlvamZaNlhGR3…
Gilead (GILD) Stock Looks Below Fair Value But Earnings Already Look Priced In - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxNY1E2bG4zV2VnUU9lZVhURnJyd1ctbllUaGdvSHQyRnZFSXZXZWdDbUhSc2hPR3dkU0JqV09ONzhrTmVsVXc5WUZJV2RDSWs5aUVlUmp0U2kxdHlHSzJ2WHd1ZU8zSHFoQ3E4VHJQRWhCLXRySkZTU3RaTThHLXFidWtOaVRRNl8xeVlnaD…
Gilead Sciences Stock (GILD) Opinions on Recent Congressional Insider Activity - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPQk1DTTdDeWFIb0JSZWdIamtYVzlxcnJ5THpBM2lfR0VLQ1lqamRMVS16eThoOUcyZjA3UmpNTkVlVzdsYVJtV04tUy05S1NVQkZ5Q2hMa1NzUDQxUThNcU5Qc1hGSTV3NUs4eEg5azhEX0xyaWJGQm93UmFnejg2bk5UdUM3bGs2bWV6YT…
Gilead Sciences Just Told Investors What to Watch Before December 23. Here’s What the Data Says About GILD Stock. - TIKR.com
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxQMy1FZks3blJfcHlFUXMxclRvdWtELUZ1Vk80amFiMlJKUGdIamE3UjJmX3JmOXpUN2ZTRXBEWm5JdF9KejJXMW5DZ1k5MDlydTZUdkVxUlVUQ1JIN3I0WVowTlRRS1dscGtKOC1tQjNLZjd5dGNEanZweFp3UUsxc193blRFZjR2WjFMTV…
GILD Stock Jumps After Winning Accelerated FDA Approval For HDV Treatment - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxOUThkM1dJSzl0OTlsZEh6Zzc3U3c0czZWMFNkenZtam1Xek9oTG54WTMya0V4OFFjaTZTcHd3MUdCN054NHFtcjQ0OUpnN2dxNW1kV1N6T19EYXhHWXdKbkJpbUkxQ0ZXUExYMG8xTVYyX254YlI1T1Y5ak9meFRPYUlBSWNHbW1QN1pyc1…
GILD — Frequently Asked Questions
What is the current share price of Gilead Sciences, Inc. (GILD)?
As of 2026-07-14 21:23 PDT, Gilead Sciences, Inc. (GILD) trades at $130.04 on NasdaqGS. Its 52-week range is $105.47 to $153.91.
What is the market capitalisation of GILD?
Gilead Sciences, Inc. (GILD) has a market capitalisation of $161.45B on NasdaqGS.
What is the P/E ratio of GILD?
GILD trades at a trailing price-to-earnings (P/E) ratio of 17.69. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 6.63.
Does GILD pay a dividend?
Gilead Sciences, Inc. (GILD) currently offers a dividend yield of 2.61%.
What is the return on equity (ROE) of GILD?
GILD has a return on equity (ROE) of 43.36%. Its return on capital employed (ROCE) is 21.23%.
Is GILD a good stock to buy?
This page provides a data-driven analysis of Gilead Sciences, Inc. (GILD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.